Ravagalimab

DRUG3 trials

Sponsors

AbbVie

Conditions

Healthy VolunteersRheumatoid ArthritisSjogren's Syndrome (SS)

Phase 1

A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

CompletedNCT06402513

AbbVieHealthy Volunteers

Start: 2024-06-24End: 2024-10-08Updated: 2024-10-21

Phase 2

An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)

WithdrawnNCT05217472

AbbVieSjogren's Syndrome (SS)

Start: 2020-03-06End: 2022-05-15Updated: 2022-02-01

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

RecruitingNCT06972446

AbbVieRheumatoid Arthritis

Start: 2025-06-20End: 2027-11-01Target: 180Updated: 2026-03-27